Mustang Bio Q3 2026: $14.3M Cash, Wider Loss, New Nasdaq MVLS Delisting Risk
MBIO is trading near its 52-week low of $0.35 (12% above the low).
Summary
Mustang Bio reported a $2,991 thousand nine-month net loss and $14.3 million of cash at September 30, 2026, and disclosed that its market value of listed securities is below the new $5 million Nasdaq minimum, a rule that would allow immediate delisting with no cure period if it takes effect.
Key Events · Earnings and Guidance · MBIO
-
Q3 Loss Widens, Cash Falls
Nine-month net loss was $2,991 thousand versus $1,383 thousand a year earlier, and cash and cash equivalents fell to $14.3 million from $17.3 million at December 31, 2025.
-
Twelve-Month Runway Stated
Management says it believes it has sufficient cash and cash equivalents to fund operations for at least twelve months from the issuance date of these financial statements.
-
New Nasdaq MVLS Delisting Risk
The company discloses its market value of listed securities is currently below the $5 million minimum under new Nasdaq Rule 5550(a)(6); if the stayed rule takes effect, a 30-business-day shortfall triggers immediate suspension and delisting with no cure period.
-
Bid-Price Grace Period Runs to April 2027
Nasdaq granted a second 180-day period until April 12, 2027 to regain the $1.00 minimum bid price, which the company says it may cure with a reverse stock split if necessary.
Analysis · MBIO · Life Sciences
A second Nasdaq listing threat now overshadows the widening loss and shrinking cash pile in Mustang Bio's third-quarter report. The company says its market value of listed securities sits below the $5 million minimum under a newly adopted rule (currently stayed), and unlike the bid-price deficiency there is no cure period: if the rule takes effect and the shortfall persists 30 business days, delisting could be immediate. Against that, management states it has enough cash to fund operations for at least twelve months from the filing date, so this report carries no near-term going-concern warning.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBIO was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.35 to $1.43. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.